ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.80 and traded as high as $6.29. ImmuCell shares last traded at $6.25, with a volume of 15,281 shares changing hands.
ImmuCell Stock Performance
The company has a 50 day moving average price of $6.45 and a 200-day moving average price of $5.83. The company has a current ratio of 3.85, a quick ratio of 1.99 and a debt-to-equity ratio of 0.28. The company has a market cap of $57.92 million, a P/E ratio of 33.69 and a beta of 0.29.
ImmuCell (NASDAQ:ICCC - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.The company had revenue of $6.45 million for the quarter.
Hedge Funds Weigh In On ImmuCell
Hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC bought a new stake in ImmuCell during the 4th quarter worth $149,000. Northern Trust Corp grew its position in ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 14,982 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock worth $500,000 after acquiring an additional 2,907 shares during the last quarter. Institutional investors own 13.47% of the company's stock.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Stories
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
